Please login to the form below

Not currently logged in
Email:
Password:

Eyevensys

This page shows the latest Eyevensys news and features for those working in and with pharma, biotech and healthcare.

Spark set to file eye disease gene therapy next year

Spark set to file eye disease gene therapy next year

Others include Bristol-Myers Squibb-backed Eyevensys, GenSight Biologics (supported by Novartis), Oxford Biomedica, Avalanche Biotechnologies, Applied Genetic Technologies, and ReGenxbio. .

Latest news

  • Boehringer backs gene therapy firm Eyevensys Boehringer backs gene therapy firm Eyevensys

    Invests in French eye disease specialist.  . Boehringer Ingelheim has announced an equity investment in French gene therapy firm Eyevensys, which specialises in the treatment of eye diseases. ... Eyevensys was set up in 2009 and raised 1.6m in its first

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Aurora Healthcare Communications

We're a leading healthcare strategic communications agency helping pharmaceutical companies adapt fast to improve the lives of patients and healthcare...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story
How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?
The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19
The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...

Infographics